Insight Molecular Diagnostics (IMDX) Debt to Equity: 2020-2025
Historic Debt to Equity for Insight Molecular Diagnostics (IMDX) over the last 5 years, with Sep 2025 value amounting to -$0.11.
- Insight Molecular Diagnostics' Debt to Equity fell 281.62% to -$0.11 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.11, marking a year-over-year decrease of 281.62%. This contributed to the annual value of -$0.02 for FY2024, which is 116.43% down from last year.
- As of Q3 2025, Insight Molecular Diagnostics' Debt to Equity stood at -$0.11, which was down 118.30% from $0.63 recorded in Q2 2025.
- In the past 5 years, Insight Molecular Diagnostics' Debt to Equity registered a high of $0.63 during Q2 2025, and its lowest value of -$0.11 during Q3 2025.
- Over the past 3 years, Insight Molecular Diagnostics' median Debt to Equity value was $0.02 (recorded in 2025), while the average stood at $0.09.
- Its Debt to Equity has fluctuated over the past 5 years, first spiked by 3,456.76% in 2023, then tumbled by 281.62% in 2025.
- Quarterly analysis of 5 years shows Insight Molecular Diagnostics' Debt to Equity stood at $0.02 in 2021, then plummeted by 85.07% to $0.00 in 2022, then surged by 3,456.76% to $0.11 in 2023, then crashed by 116.43% to -$0.02 in 2024, then crashed by 281.62% to -$0.11 in 2025.
- Its Debt to Equity stands at -$0.11 for Q3 2025, versus $0.63 for Q2 2025 and $0.04 for Q1 2025.